Posted by Michael Wonder on 18 Feb 2025
Rznomics liver cancer drug candidate secures fast track designation
17 February 2025 - Second fast track designation following brain cancer approval.
Rznomics announced on 14 February 2025 that its anti-cancer drug, RZ-001, has received fast track designation from the US FDA for the treatment of hepatocellular carcinoma.
